Nicotine receptor ligands

Medicinal Chemistry Research

Volumn 6, Issue 7-8, 1996, Pages 465-486

  Glennon, Richard A ^a   Dukat, Małgorzata ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 1842611756     PISSN: 10542523     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (74)

1. Williams, M.; Sullivan, J. P.; Arneric, S. P. Neuronal nicotinic receptors. Drug News Perspect. 7, 205-223, 1994.
2. Sargent, P. B. The diversity of neuronal nicotinic acetylcholine receptors. Ann. Rev. Neurosci. 16, 403-443, 1993.
3. Arneric, S. P.; Sullivan, J. P.; Williams, M. Neuronal nicotinic acetylcholine receptors. Novel targets for central nervous system therapeutics. In: Psychopharmacology: The Fourth Generation of Progress. F. E. Bloom; D. J. Kupfer, eds., Raven Press, NY, 1995. pp 95-110.
4. Galzi, J.-L.; Changeux, J.-P. Neuronal nicotinic receptors: Molecular organization and regulation. Neuropharmacology 34, 563-582, 1995.
5. Wonnacott, S. Brain nicotine binding sites. Human Toxicol. 6, 343-353, 1987.
6. Nordberg, A. A comparison of the (S)(-) and (R)(+) enantiomers of nicotine with respect to pharmacological and behavioral effects and receptor binding properties in experimental animal and man. Med. Chem. Res. 2, 522-529, 1993.
7. Glennon, R. A.; Herndon, J. L., Dukat, M. Epibatidine-aided studies toward definition of a nicotine receptor pharmacophore. Med. Chem. Res. 4, 461-473, 1994.
8. 3H-labeled azetidine analogue of nicotine. Biochem. Pharmacol. 36, 2337-2341, 1987.
9. Glassco, W.; May, E. L.; Damaj; M. I.; Martin, B. R. In vivo and in vitro activity of some N-substituted (±)nornicotine analogs. Med. Chem. Res. 4, 273-282, 1993.
10. Glennon, R. A.; Maarouf, A.; Fahmy, S.; Martin, B.; Fan, F.; Yousif, Y.; Shafik, R. M.; Dukat, M. Structure-activity relationships of simple nicotine analogs. Med. Chem. Res. 2, 546-551, 1993.
11. Lin, N.-H.; Carrera, G. M.; Anderson, D. J. Synthesis and evaluation of nicotine analogs as neuronal nicotinic acetylcholine receptor ligands. J. Med. Chem. 37, 3542-3553, 1994.
12. Secor, H. V.; Edwards, W. B. Nicotine analogues: Synthesis of pyridylazetidines. J. Org. Chem. 44, 3136-3140, 1979.
13. 125I-α-bungarotoxin receptor subtypes. J. Pharmacol. Exp. Ther. 274, 164-171, 1995.
14. Glennon, R. A.; Dukat, M.; Feidler, W.; Dumas, D. Rigid analogs of nicotine. MEDI115, 210th American Chemical Society Meeting, Chicago, IL, August 20-24, 1995.
15. Buckingham, S. D.; Balk, M. L.; Lummis, S. C. R.; Jewess, P.; Sattelle, D. B. Actions of nitromethylenes on an α-bungarotoxin-sensitive neuronal nicotinic acetylcholine receptor. Neuropharmacology 34, 591-597, 1995.
16. Garvey, D. S.; Wasicak, J. T.; Elliott, R. L.; Lebold, S. A.; Hettinger, A.-M.; Carrera, G. M.; Lin, N.-H.; He, Y.; Holladay, M. W.; Anderson, D. J.; Cadman, E. D.; Raszkiewicz, J. L.; Sullivan, J. P., Arneric, S. P. Ligands for brain cholinergic channel receptors: Synthesis and in vitro characterization of novel isoxazoles and isothiazoles as biosteric replacements for the pyridine ring in nicotine. J. Med. Chem. 37, 4455-4463, 1994.
17. Garvey, D. S.; Wasicak, J. T.; Decker, M. D.; Brioni, J. D.; Buckley, M. J.; Sullivan, J. P.; Carrera, G. M., Holladay, M. W.; Arneric, S. P.; Williams, M. Novel isoxazoles which interact with brain cholinergic channel receptors have intrinsic cognitive enhancing and anxiolytic activities. J Med. Chem. 37, 1055-1059, 1994.
18. Arneric, S. P.; Sullivan, J. P.; Briggs, C. A.; Donnelly-Roberts, D.; Anderson, D. J.; Raszkiewicz, J. L.; Hughes, M. L.; Cadman, E. D.; Adams, P.; Garvey, D. S.; Wasicak, J. T.; Williams, M. (S)-3-Methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): A novel cholinergic ligand with cognition enhancing and anxiolytic activities I. In vitro characterization. J. Pharmacol. Exp. Ther. 270, 310-318, 1994.
19. Decker, M. W.; Brioni, J D.; Sullivan, J. P.; Buckley, M. J.; Radek, R. J.; Raszkiewicz, J. L.; Kang, C. H.; Kim, D. J. B.; Giardina, W. J.; Wasicak, J. T.; Garvey, D. S.; Williams, M.; Arneric, S. P. (S)-3-Methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): A novel cholinergic ligand with cognition enhancing and anxiolytic activities. II. In vivo characterization. J. Pharmacol. Exp. Ther. 270, 319-328, 1994.
20. Holladay, M. W.; Daanen, J.; Bai, H.; He, Y.; Lebold, S. A.; Pavik, P.; Wasicak, J. T.; Gunn, D. E.; Lin, N.; Abreo, M.; Garvey, D. S.; Martin, Y.; Andeson, D. J.; Campbell, J. E.; Donnelly-Roberts, D.; Piattoni-Kaplan, M.; Sullivan, J. P., Williams, M.; Arneric, S. P. Structure-activity and molecular modeling studies on nicotinic acetylcholine receptor ligands. MEDI114, 210th American Chemical Society Meeting, Chicago, IL, August 20-24, 1995.
21. Dukat, M.; Damaj, M. I.; Glassco, W.; Dumas, D.; May, E. L.; Martin, B. R.; Glennon, R. A. Epibatidine: A high-affinity nicotine receptor ligand. Med. Chem. Res. 4, 131-139, 1994.
22. Kanne, D. B.; Ashworth, D. J.; Cheng, M. T.; Mutter, L. C.; Abood, L.G. Synthesis of the first highly potent bridged nicotinoid. 9-Azabicyclo[4.2.1]nona[2,3-c]pyridine (pyrido[3,4-b]homotropane). J. Am. Chem. Soc. 108, 7864-7865, 1986.
23. Chavdarian, C. G.; Seeman, J. I.; Wooten, J. B. Bridged nicotines. cis-2,3,3a,4,5,9b-hexahydro-1-methyl-1H-pyrrolo[2,3-f]quinoline. J. Org. Chem. 48, 492-494, 1983.
24. Glassco, W.; Suchocki, J.; George, C.; Martin, B. R.; May, E. L. Synthesis, optical resolution, absolute configuration, and preliminary pharmacology of (+)- and (-)-cis-2,3,3a,4,5,9b-hexahydro-1-methyl-1H-pyrrolo[3,2-h]isoquinoline, a structural analog of nicotine. J. Med. Chem. 36, 3381-3385, 1993.
25. Lloyd, G. K.; McDonald, I. A., Vernier, J.-M.; Elliot, K.; Ellis, S. B.; Sacaan, A.; Rao, T. S.; Chavez-Noriega, L.; Johnson, E. C.; Velicelebi, M. F.; Harpold, M. Subtype-selective cholinergic ion channel agonists as potential antiparkinson agents. The Cholinergic Synapse: Structure, Function and Regulation. Baltimore MD, November 6-10, 1994.
26. Kanne, D. B.; Abood, L. G. Synthesis and biological characterization of pyridohomotropanes. Structure-activity relationships of conformationally restricted nicotinoids. J. Med. Chem. 31, 506-509, 1988.
27. Sheridan, R. P.; Nilakantan, R.; Dixon, J. S.; Venkataraghavan, R. The ensemble approach to distance geometry: Application to the nicotinic pharmacophore. J. Med. Chem. 29, 899-906, 1986.
28. Dukat, M. 208/210 a.k.a. Epibatidine. Med. Chem. Res. 4, 433-439, 1994.
29. Badio, B.; Garraffo, H. M.; Spande, T. F.; Daly, J. W. Epibatidine: Discovery and definition as a potent analgesic and nicotinic antagonist. Med. Chem. Res. 4, 440-448, 1994.
30. Dukat, M.; Dumas, D.; Damaj, M. I.; Glassco, W.; May, E. L.; Martin, B.; Glennon, R. A. Epibatidine: A high-affinity nicotine receptor ligand. International Symposium on Nicotine: The Effects of nicotine on Biological Systems. II. P. B. S. Clarke, M. Quik, K. Thurau; F. Adlkofer, eds., Birkhauser-Verlag, Basel, 1994. p 31.
31. 3H]methylcarbamylcholine in rat brain. Eur. J. Pharmacol. 253, 261-267, 1994.
32. 3H]dopamine release from striatal synaptosomes: Pharmacological characterisation. J. Neurochem. 54, 937-945, 1990.
33. Schmeller, T.; Saurwein, M.; Sporer, F.; Wink, M.; Müller, W. E. Binding of quinolizidine alkaloids to nicotinic and muscarinic acetylcholine receptors. J. Nat. Prod. 57, 1316-1319, 1994.
34. 3H]Cytisine binding to nicotinic cholinergic receptors in brain. Mol. Pharmacol. 39, 9-12, 1992.
35. Papke, R. L.; Heinemann, S. F. Partial agonist properties of cytisine on neuronal nicotinic receptors containing the β2 subunit. Mol. Pharmacol 45, 142-149, 1994.
36. Boekelheide, V.; Weinstock, J.; Grundon, M. F.; Sauvage, G. L.; Agnello, E. J. The structure of β-erythroidine and its derivatives. J. Am. Chem Soc. 75, 2550, 1953.
37. Damaj, M. L; Welch, S. P.; Martin, B. R. In vivo pharmacological effects of dihydro-β-erythroidine, a nicotinic antagonist, in mice. Psychopharmacology 117, 67-73, 1995.
38. Decker, M. W.; Anderson, D. J.; Brioni, J. D.; Donnelly-Roberts, D. L.; Kang, C. H.; O'Neill, A. B.; Piattoni-Kaplan, M.; Swanson, S.; Sullivan, J. P. Erysodine, a competitive antagonist at neuronal nicotinic acetylchole receptors. Eur. J. Pharmacol. 280, 79-89, 1995.
39. Wonnacott, S. Neurotoxin probes for nicotinic receptors. In Neurotoxins and their Pharmacological Implications. P. Jenner, ed., Raven Press, NY 1987 pp 209-231.
40. Luetje, C. W.; Wada, K.; Rogers, S.; Abramson, S. N; Tsuji, K., Heinemann, S.; Patrick; J. Neurotoxins distinguish between different neuronal nicotinic acetylcholine receptor subunit combinations. J. Neurochem. 55, 632-640, 1990.
41. Warnick, J. E.; Jessup, P. J.; Overman, L. E.; Eldefrawi, M. E.; Nimit, Y.; Daly, J. W.; Albuquerque, E. X. Pumiliotoxin-C and synthetic analogues. Mol. Pharmacol. 22, 565-573, 1982.
42. Thomas, P.; Stephens, M.; Wilkie, G.; Amar, M.; Lunt, G. G.; Whiting, P.; Gallagher, T.; Pereira, E.; Alkondon, M.; Albuquerque, E. X.; Wonnacott, S. (+)-Anatoxin-a is a potent agonist at neuronal nicotinic acetylcholine receptors. J. Neurochem. 60, 2308-2311, 1993.
43. Sardina, F. J.; Howard, M. H.; Koskinen, A. M. P.; Rapoport, H. Chirospecific synthesis of nitrogen and side chain modified analogues of (+)anatoxin J. Org. Chem. 54, 4654-4660, 1989.
44. Howard, M. H.; Sardina, F. J.; Rapoport, H. Chirospecific syntheses of nitrogen and side chain modified anatoxin. Synthesis of (1R)-anatoxinol and (1R)-anatoxinic acid derivatives. J. Org. Chem. 55, 2829-2838, 1990.
45. Wonnacott, S.; Jackman, S.; Swanson, K. L.; Rapoport, H.; Albequerque, E. X. Nicotinic pharmacology of anatoxin analogs. II. Side chain structure-activity relationships at neuronal nicotinic ligand binding sites. J. Pharmacol Exp. Ther 259, 387-391, 1991.
46. Hernandez, A.; Rapoport, H. Conformationally constrained analogues of anatoxin. Chirospecific synthesis of s-trans carbonyl ring-fused analogues. J. Org. Chem. 59, 1058-1066, 1994.
47. Wonnacott, S., Swanson, K. L.; Albuquerque, E. X.; Huby, N. J.; Thompson, P.; Gallagher, T. Homoanatoxin: a potent analogue of anatoxin-a. Biochem. Pharmacol. 43, 419-423, 1992.
48. Thompson, P. E.; Manallack, D. T.; Blaney, F. E.; Gallagher, T. Conformational studies on (+)-anatoxin-a and derivatives. J. Comput. Aided Mol. Des. 6, 287-298, 1992.
49. Spivak, C. E.; Waters, J.; Witkop, B.; Albuquerque, E. X. Potencies and channel properties induced by semirigid agonists at frog nicotinic acetylcholine receptors. Mol. Pharmacol. 23, 337-343, 1983.
50. 125I]-α-bungarotoxin. J. Neurosci. 5, 1307-1315, 1985.
51. Clarke, P. B. S. The fall and rise of neuronal α-bungarotoxin binding proteins. Trends Pharmacol Sci. 13, 407-413, 1992.
52. 7 nicotinic acetylcholine receptor responses to novel ligands. Neuropharmacology 34, 583-590, 1995.
53. Pugh, P. C.; Corriveau, R. A.; Conroy, W. G.; Berg, D. K. Novel subpopulation of neuronal acetylcholine receptors among those binding α-bungarotoxin. Mol. Pharmacol. 47, 717-725, 1995.
54. Kosuge, T.; Tsuji, K.; Hirai, K. Isolation of neosurugatoxin from the Japanese ivory shell Babylonia japonica. Chem. Pharm. Bull. 30, 3255-3259, 1982.
55. Hayashi, E.; Isogai, M.; Kagawa, Y.; Takayanagi, N.; Yamada, S. Neosurugatoxin, a specific antagonist of nicotinic acetylcholine receptors. J. Neurochem. 42, 1491-1494, 1984.
56. Yamada, S.; Kagawa, Y.; Takayanagi, N.; Nakayama, K.; Tsuji, K.; Kosuge, T.; Hayashi, E.; Okada, K.; Inoue, S. Comparison of antinicotinic activity by neosurugatoxin and the structurally related compounds. J. Pharmacol. Exp. Ther. 243, 1153-1158, 1987.
57. Bai, D.; Sattelle, D. B. Neosurugatoxin blocks an α-bungarotoxin-sensitive neuronal nicotinic acetylcholine receptor. Arch. Insect Biochem. Physiol. 23, 161-167, 1993.
58. Anis, N.; Sherby, S.; Goodnow, R.; Niwa, M.; Konno, K.; Kallimopoulos, T., Bukownik, R.; Nakanishi, K.; Usherwood, P.; Eldefrawi, A.; Eldefrawi, M. Structure-activity relationships of philanthrotoxin analogs and polyamines on N-methyl-D-aspartate and nicotinic acetylcholine receptors. J. Pharmacol. Exp. Ther. 254, 764-773, 1990.
59. Rapier, C.; Wonnacott, S.; Lunt, G. G.; Albuquerque, E. X. The neurotoxin histrionicotoxin interacts with the putative ion channel of the nicotinic acetylcholine receptors in the central nervous system. FEBS Lett. 212, 292-296, 1987.
60. Arias, H. P.; Johnson, D. A. Differential agonist-induced displacement of quinacrine and ethidium from their respective histrionicotoxin-sensitive binding sites on the Torpedo acetylcholine receptor. Biochemistry 34, 1589-1595, 1995.
61. Groebe, D. R.; Abramson, S. N. Lophotoxin is a slow binding irreversible inhibitor of nicotinic acetylcholine receptors. J. Biol. Chem. 270, 281-286, 1995.
62. Culver, P.; Burch, M.; Potenza, C.; Wasserman, L.; Fenical, W.; Taylor, P. Structure-activity relationships for the irreversible blockade of nicotinic receptor agonist sites by lophotoxin and congeneric diterpene lactones. Mol. Pharmacol. 28, 436-444, 1985.
63. Abramson, S. N.; Trischman, J. A.; Tapiolas, D. M.; Harold, E. E.; Fenical, W.; Taylor, P. Structure / activity and molecular modeling studies of the lophotoxin family of irreversible nicotinic receptor antagonists. J. Med. Chem. 34, 1798-1804, 1991.
64. Abramson, S. N.; Fenical, W., Taylor, P. Lophotoxins: Irreversible active-site directed inhibitors of nicotinic acetylcholine receptors. Drug Dev. Res. 24: 297-312, 1991.
65. Abood, L. G.; Salles, K. S.; Maiti, A. Structure-activity studies of carbamate and other esters: Agonists and antagonists to nicotine. Pharmacol. Biochem. Behav. 30, 403-408, 1988.
66. 3H]-Methylcarbamylcholine: A new radioligand for studying brain nicotinic receptors. Biochem. Pharmacol. 35, 4199-4202, 1986.
67. Abood, L. G.; Lerner-Marmarosh, N.; Wang, D.; Saraswati, M. Structure-activity relationships of various nicotinoids and N-substituted carbamate esters of choline and other amino alcohols. Med. Chem. Res. 2, 552-563, 1993.
68. 3H]Mecamylamine binding to rat brain membranes. Studies with mecamylamine and nicotine analogues. Biochem Pharmacol. 40, 2105-2110, 1990.
69. Suchocki, J. A.; May, E. L.; Martin, T. J.; George, C.; Martin, B. R. Synthesis of 2-exo- and 2-endomecamylamine analogues. Structure-activity relationships for nicotinic antagonism in the central nervous system. J. Med. Chem. 34, 1003-1010, 1991.
70. Martin, T. J.; Suchocki, J. A.; May, E. L.; Martin, B. R. Pharmacological evaluation of the antagonism of nicotine's central effects by mecamylamine and pempidine J. Pharmacol. Exp. Ther. 254, 45-51, 1990.
71. Martin, B. R.; Martin, T. J.; Fan, F.; Damaj, M. I. Central actions of nicotine antagonists. Med. Chem. Res. 2, 564-577, 1993.
72. Beers, W. H.; Reich, E. Structure and activity of acetylcholine. Nature (London) 228, 917-922, 1970.
73. Hacksell, U.; Mellin, C. Stereoselectivity of nicotinic receptors. Prog. Brain Res. 79, 95-100, 1989.
74. Dukat, M.; Herndon, J. L.; Glennon, R. A. Epibatidine: Reconsideration of the nicotine receptor pharmacophore. NIDA Res. Mono. 162, 286, 1996.